prikaz prve stranice dokumenta The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status
  Preuzmi
PDF 5.57 MB
Znanstveni rad - Izvorni znanstveni rad
The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status
Biomolecules and Biomedicine, 24 (2024), 2; 256-261. https://doi.org/10.17305/bb.2023.9868
Gatalica, Zoran; Kuzmova, Nataliya; Rose, Inga; Ulamec, Monika; Perić-Balja, Melita; Skenderi, Faruk; Vranic, Semir

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Gatalica, Z., Kuzmova, N., Rose, I., Ulamec, M., Perić Balja, M., Skenderi, F. i Vranic, S. (2024). The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status. Biomolecules and Biomedicine, 24. (2), 256-261. doi: 10.17305/bb.2023.9868

Gatalica, Zoran, et al. "The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status." Biomolecules and Biomedicine, vol. 24, br. 2, 2024, str. 256-261. https://doi.org/10.17305/bb.2023.9868

Gatalica, Zoran, Nataliya Kuzmova, Inga Rose, Monika Ulamec, Melita Perić Balja, Faruk Skenderi i Semir Vranic. "The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status." Biomolecules and Biomedicine 24, br. 2 (2024): 256-261. https://doi.org/10.17305/bb.2023.9868

Gatalica, Z., et al. (2024) 'The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status', Biomolecules and Biomedicine, 24(2), str. 256-261. doi: 10.17305/bb.2023.9868

Gatalica Z, Kuzmova N, Rose I, Ulamec M, Perić Balja M, Skenderi F, i sur.. The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status. Biomolecules and Biomedicine [Internet]. 11.03.2024. [pristupljeno 28.12.2024.];24(2):256-261. doi: 10.17305/bb.2023.9868

Z. Gatalica, et al., "The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status", Biomolecules and Biomedicine, vol. 24, br. 2, str. 256-261, Ožujak 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:253311. [Citirano: 28.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:253311
Podaci o radu
Naslov (engleski)The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status
AutorZoran Gatalica
MBZ: 138016
AutorNataliya Kuzmova
AutorInga Rose
AutorMonika Ulamec
AutorMelita Perić-Balja
AutorFaruk Skenderi
AutorSemir Vranic
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PATOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patologija
Sažetak (engleski)
In the current study, we assessed the prevalence and molecular features of HER2-low phenotype in the apocrine carcinomas of the breast (ApoCa) and its relationship with tumor-infiltrating lymphocytes (TILs). A cohort of 64 well-characterized therapy-naïve ApoCa was used. The TIL distribution was assessed using the hematoxylin and eosin whole slide/scanned images following the international TILs working group recommendations. Next-generation sequencing (NGS) was performed in a subset of HER2-low ApoCa. All patients were women, with a mean age of 62 years. Forty-three carcinomas were pure apocrine carcinoma (PAC; ER−/AR+), and the remaining 21 were classified as apocrine-like carcinomas (ALCs; ER+/−, AR+/−). HER2/neu was positive (score 3+ by IHC and/or amplified by FISH) in 20/43 (47%) PAC and 4/21 (19%) ALC. The prevalence of HER2-low expression (scores 1+ or 2+ without HER2 amplification) in ApoCa was 39% without significant differences between PAC and ALC (P = 0.14); however, the HER2-low phenotype was more prevalent in triple-negative PAC than in ALC (P < 0.001). Levels of TILs were low (≤10%) in 74% of ApoCa (median 5%, range 0%–50%). TIL levels were significantly higher in ALC than in PAC (P = 0.02). HER2 status had no impact on TIL distribution (P = 0.45). The genomic profile of HER2-low ApoCa was similar to other subtypes of ApoCa. ApoCa has predominantly low TIL, particularly PAC. The prevalence of the HER2-low phenotype in ApoCa is high, which should have therapeutic and clinical implications given the recently approved therapies with antibody–drug conjugates (ADCs) for HER2-low breast cancers.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiomolecules and Biomedicine
Brojčani podacivol. 24, br. 2, str. 256-261
p-ISSN2831-0896
e-ISSN2831-090X
DOIhttps://doi.org/10.17305/bb.2023.9868
URN:NBNurn:nbn:hr:105:253311
Datum objave publikacije2024-03-11
URL dokumentahttps://bjbms.org/ojs/index.php/bjbms/article/view/9868
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-05-20 07:42:03